|
C12ORF29 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62470037423645E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
1.02709951654845E-10 |
| Normal-vs-Stage3 |
1.32116539930394E-14 |
| Normal-vs-Stage4 |
3.18844950442099E-12 |
| Stage1-vs-Stage2 |
3.884400E-01 |
| Stage1-vs-Stage3 |
8.734000E-01 |
| Stage1-vs-Stage4 |
2.447000E-01 |
| Stage2-vs-Stage3 |
4.717800E-01 |
| Stage2-vs-Stage4 |
8.366000E-01 |
| Stage3-vs-Stage4 |
3.023000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.22044604925031E-16 |
| Normal-vs-AfricanAmerican |
3.41739999965007E-07 |
| Normal-vs-Asian |
1.33870692309301E-12 |
| Caucasian-vs-AfricanAmerican |
6.630400E-01 |
| Caucasian-vs-Asian |
2.094600E-01 |
| AfricanAmerican-vs-Asian |
7.750400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.44089209850063E-16 |
| Normal-vs-Female |
1.62447832963153E-12 |
| Male-vs-Female |
5.537800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62891922173003E-12 |
| Normal-vs-Age(41-60Yrs) |
2.22044604925031E-16 |
| Normal-vs-Age(61-80Yrs) |
1.65500946280872E-12 |
| Normal-vs-Age(81-100Yrs) |
1.676130E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.020800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.845000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.887400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.597400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.322400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.541800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.869200E-01 |
| Classical-VS-Follicular |
5.704200E-02 |
| Classical-VS-Other |
6.300000E-01 |
| Classical-VS-Normal |
1.23689947173489E-10 |
| Tall-VS-Follicular |
3.394000E-01 |
| Tall-VS-Other |
7.800400E-01 |
| Tall-VS-Normal |
1.0469000000235E-08 |
| Follicular-VS-Other |
8.315200E-01 |
| Follicular-VS-Normal |
2.65731880944031E-12 |
| Other-VS-Normal |
1.721050E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
<1E-12 |
| Normal-vs-N1 |
9.2548191332753E-13 |
| N0-vs-N1 |
8.810200E-01 |
|
|
